Start a pivotal study of the methylmalonic acidemia therapeutic (mRNA-3705)
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Nov 2024
- Due
- 30 Jun 2025
- Checked
- 10 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company expects to start a pivotal study in the first half of 2025.”
What we found
Evidence strength A What the grades mean
The pivotal study did not start by the June 2025 deadline. Later filings moved the registrational study to 2026, and by 2026 the decision was deferred.
-
A Moderna 8-K filed 2025-11-06
“The Company expects to start a registrational study in 2026.” ✓ confirmed on the page
-
A Moderna 10-Q filed 2025-11-06
“We expect to start a registrational study in 2026.” ✓ confirmed on the page
-
A Moderna 10-Q filed 2026-05-01
“We are deferring our decision on a pivotal trial for mRNA-3705 until PA registrational data readout.” ✓ confirmed on the page
Market reaction: the shares moved +4.5% against the S&P 500 over the three sessions around the disclosure (5 Nov 2025 to 10 Nov 2025). What this measures
Checked 10 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 1 versions
-
Version 1 · original · stated 7 Nov 2024
Deadline 30 Jun 2025 (“in the first half of 2025”) · wording expected
-
Version 2 · stated 14 Feb 2025
Deadline 31 Dec 2025 (“in 2025”) · wording expected
“The Company expects to start a registrational study in 2025.”
-
Version 3 · stated 6 Nov 2025
Deadline 31 Dec 2026 (“in 2026”) · wording expected
“The Company expects to start a registrational study in 2026.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Start
- Deliverable
- Pivotal study of mRNA-3705 for methylmalonic acidemia
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-MRNA-006232 · Corrections policy